Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsors and Collaborators: |
Rambam Health Care Campus zufglobus.com |
---|---|
Information provided by: | Rambam Health Care Campus |
ClinicalTrials.gov Identifier: | NCT00243165 |
This study will include 60 patients with early breast cancer referred to receive adjuvant chemotherapy with AC ( adriamycin- cyclophosphamide) or CAF ( adriamycin- cyclophosphamide- 5- fluorouracil ) combinations. These patients will receive every day one spoon of Lifemel honey or regular honey ( double blind)- during the adjuvant chemotherapy .Every week a WBC count will be performed in order to record the influence of Lifemel on myelotoxicity.
Condition | Intervention | Phase |
---|---|---|
Breast Cancer |
Behavioral: Lifemel honey intake every day |
Phase II |
Study Type: | Interventional |
Study Design: | Prevention, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Efficacy Study |
Official Title: | Lifemel Honey During Adjuvant Chemotherapy for Breast Cancer Patients to Prevent Leucopenia |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Female |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contact: Georgeta Fried, MD | 972-4-8543018 | g_fried@rambam.health.gov.il |
Principal Investigator: | Georgeta Fried, MD | Rambam Health Care Campus |
Study ID Numbers: | LifemelCTIL |
Study First Received: | October 20, 2005 |
Last Updated: | October 20, 2005 |
ClinicalTrials.gov Identifier: | NCT00243165 |
Health Authority: | Israel: Israeli Health Ministry Pharmaceutical Administration |
breast cancer honey myelosuppression chemotherapy |
Skin Diseases Hematologic Diseases Breast Neoplasms |
Leukocyte Disorders Leukopenia Breast Diseases |
Neoplasms Neoplasms by Site |